News

Switching From Reference Trastuzumab to Biosimilar for HER2 Positive Breast Cancer May Not Affect Infusion Reaction, Cardiac Dysfunction

07/10/2023

Gina Tomaine

Switching from reference trastuzumab to biosimilar trastuzumab may not have a significant effect on the frequency of infusion reaction expression or the occurrence of cardiac dysfunction among patients with HER2-positive breast cancer.

Switching from reference...

07/10/2023

Oncology

News

Bevacizumab Biosimilar Demonstrates Efficacy, Acceptable Toxicity Compared to Reference Bevacizumab for Patients With Locally Advanced and Advanced NSCLC

06/16/2023

Gina Tomaine

Bevacizumab biosimilar demonstrated comparable efficacy to reference bevacizumab among patients with locally advanced and advanced non-small-cell lung cancer, with an acceptable toxicity profile, according to a retrospective study.

Bevacizumab biosimilar...

06/16/2023

Oncology

News

Filgrastim Biosimilar Demonstrated Comparable Efficacy to Originator Filgrastim in Peripheral Blood CD34+ Stem Cell Mobilization Among Patients With Hematologic Malignancies

05/25/2023

Jordan Kadish

A filgrastim biosimilar had similar efficacy in peripheral blood CD34+ stem cell mobilization for both autologous and allogeneic stem cell transplantation compared to the referent among patients with hematologic malignancies.

A filgrastim biosimilar had...

05/25/2023

Oncology

News

Pegfilgrastim and Biosimilar Yielded Promising Efficacy, Safety Among Patients With MM Post-AlloSCT

05/24/2023

Jordan Kadish

Pegfilgrastim and a pegfilgrastim biosimilar yielded more promising efficacy and safety results than a filgrastim biosimilar among patients with multiple myeloma who had undergone autologous stem cell transplantation.

Pegfilgrastim and a...

05/24/2023

Oncology

News

New Version of Bevacizumab Biosimilar Found Bioequivalent to Referent

05/23/2023

Allison Casey

In a phase 1 trial, a new iteration of the MB02 bevacizumab biosimilar was also found to be bioequivalent to the reference bevacizumab.

In a phase 1 trial, a new...

05/23/2023

Oncology

News

HD201 Comparable to Referent Trastuzumab for HER2-Positive Breast Cancer

05/19/2023

Derek Cowsert

The TROIKA trial demonstrated comparable efficacy between HD201 and referent trastuzumab for the neoadjuvant treatment of HER2-positive breast cancer.

The TROIKA trial demonstrated...

05/19/2023

Oncology

News

No Difference in Risk of Febrile Neutropenia Between Patients Receiving Pegfilgrastim Biosimilar vs Originator

05/16/2023

Jordan Kadish

According to findings from a real-world cohort study, no difference in the risk of febrile neutropenia was observed between patients who received biosimilar pegfilgrastim vs originator pegfilgrastim.

According to findings from a...

05/16/2023

Oncology

News

05/12/2023

Jordan Kadish

According to findings from a phase 3 trial, biosimilar rituximab had comparable efficacy and safety to originator rituximab among patients with diffuse large B-cell lymphoma.

According to findings from a...

05/12/2023

Oncology

News

No Association Observed Between Biosimilar Rituximab Exposure and Hypersensitivity Hospitalization

05/12/2023

Jordan Kadish

According to findings from a 2-cohort study, exposure to biosimilar rituximab at initiation, switch, or over time was not associated with hospitalization due to hypersensitivity, compared to originator rituximab.

According to findings from a...

05/12/2023

Oncology

News

Cardiac Safety of SB3 Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer

05/09/2023

Allison Casey

In a phase 3 trial, the SB3 trastuzumab biosimilar demonstrated comparable cardiac safety to reference trastuzumab among patients with HER2-positive early or locally advanced breast cancer.

In a phase 3 trial, the SB3...

05/09/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology